Study on the Effect of Inulin in Infant Formula on Gut Health

NCT ID: NCT01515644

Last Updated: 2013-04-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

164 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-10-31

Study Completion Date

2013-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study the effect of Infant formula with added Inulin will be compared with the effect of Infant formula without Inulin on the Bifidobacterium level in stool.

It is expected that drinking Infant formula with added Inulin will result in higher beneficial bacteria level in stool compared to an Infant formula without Inulin.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Infants

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention group I

Intervention group I: Powder based Infant formula with Inulin I

Group Type EXPERIMENTAL

Powder based infant formula

Intervention Type OTHER

Powder based infant formula with Inulin I

Intervention group II

Intervention group II: Powder based Infant formula with Inulin II

Group Type EXPERIMENTAL

Powder based infant formula

Intervention Type OTHER

Powder based infant formula with Inulin II

Intervention group III

Intervention group III: Powder based Infant formula without Inulin

Group Type PLACEBO_COMPARATOR

Powder based infant formula

Intervention Type OTHER

Powder based infant formula without Inulin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Powder based infant formula

Powder based infant formula with Inulin I

Intervention Type OTHER

Powder based infant formula

Powder based infant formula with Inulin II

Intervention Type OTHER

Powder based infant formula

Powder based infant formula without Inulin

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy infants between 3-4 months (91-120 days after birth) of age at day 1 of the study, with healthy growth determined based on WHO standard
* Fully formula-fed in the 28 days prior to inclusion
* Expected investigational product intake of min 500ml per day
* Written informed consent from the parents

Exclusion Criteria

* Low birth weight (LBW) less than 2,000g.
* Disorders requiring a special diet (such as food intolerance or food allergy or complaints such as reflux, constipation and cramps for which special toddler formula is required)
* Use of systemic antibiotics or antimycotics medication in the 14 days prior to the study
* Significant congenital abnormality that will interfere with the study objectives in the opinion of the investigator.
* Investigator's uncertainty about the willingness or ability of the parents to comply with the protocol requirements.
* Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study.


* Not consuming study product longer than 2 days consecutively
* Intake of study product is less than 500ml per day for 7 days
Minimum Eligible Age

3 Months

Maximum Eligible Age

4 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Danone Global Research & Innovation Center

INDUSTRY

Sponsor Role collaborator

PT. Sari Husada

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hanifah Oswari, dr., Sp.A(K), PhD

Role: PRINCIPAL_INVESTIGATOR

Research Unit of Indonesian Pediatrics Association

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Unit of Indonesian Pediatrics Association

Jakarta, , Indonesia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Indonesia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CT.01.2010

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Safety and Efficacy Study
NCT02670863 COMPLETED NA
Starter Infant Formula With Synbiotics
NCT06073652 ACTIVE_NOT_RECRUITING NA
Prebiotic in Preterm Infants
NCT03306316 COMPLETED NA